Restuccia, Eleonora
F. Hoffmann-La Roche AG
3 papers on CoChatORCID 0000-0001-5751-094X
Most cited papers
- Verified
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Swain, S. M., Miles, D., Kim, S.-B., Im, Y.-H., Im, S.-A., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., et al. (2020) · The Lancet Oncology
HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes
Cited by 922
- Verified
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
Piccart, M., Procter, M., Fumagalli, D., de Azambuja, E., Clark, E., Ewer, M. S., Restuccia, E., Jerusalem, G., Dent, S., Reaby, L., et al. (2021) · Journal of Clinical Oncology
HER2/EGFR in Cancer ResearchBreast Cancer Treatment Studies
Cited by 364
- Verified
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
Kuemmel, S., Tondini, C. A., Abraham, J., Nowecki, Z., Itrych, B., Hitre, E., Karaszewska, B., Juárez-Ramiro, A., Morales-Vásquez, F., Pérez-García, J. M., et al. (2021) · Breast Cancer Research and Treatment
HER2/EGFR in Cancer ResearchCancer Treatment and Pharmacology
Cited by 22
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free